research report      name index      key word index      corresp.unit            Page in german      Imprint + Privacy Policy   

Third-party-funded project

Clopidogrel: Mechanism of action and role as antiplatelet / anti-inflammatory drug

Project management at the University of Würzburg:

Participating scientists:

The central aspect and goal of our project was to enhance the understanding of the physiological / pathophysiological / pharmacological roles of human platelet ADP receptors and the mechanisms of Clopidogrel action. The data obtained in this project, which was supported by Sanofi-Synthelabo and Bristol-Myers Squibb, contributed to the 3-receptor concept of purinergic signaling in human platelets and identified the P2Y12 ADP receptor as molecular target for the antiplatelet drugs ticlopidine and clopidogrel. In several resulting publications, the pharmacology of platelet ADP receptors and their regulation/inhibition by Clopidogrel were described.

Key words:
    Purinergic receptors
    Antiplatelet drugs

Projekt period: from 01.2000 to 06.2002

Funding institution:
Wirtschaftsunternehmen ,Granting date: 21.01.2000


Sanofi-Synthelabo GmbH
Bristol-Myers Squibb GmbH